Full-Time
Software Test Engineer
Confirmed live in the last 24 hours
Alamar Biosciences
51-200 employees
Develops technology for protein detection and measurement
Compensation Overview
$105k - $125kAnnually
Junior, Mid
Fremont, CA, USA
This position is expected to be hybrid, coming onsite to our Fremont office at least twice a week.
You match the following Alamar Biosciences's candidate preferences
Employers are more likely to interview you if you match these preferences:
- Bachelor’s degree in computer science or a similar and 2+ years experience in software testing, including functional, regression, and performance testing.
- Working knowledge of scripting language (R Python) and/or exposure to different programming languages. Required (Cypress/ Selenium)
- Experience with issue tracking and test planning software systems (Github)
- Strong knowledge of web technologies (HTML, CSS, JavaScript)
- Experience diagnosing and debugging complex systems
- Strong communication skills and attention to detail
- Self-motivation with a positive “can do” attitude and attention to details.
- Design and develop test methods and test protocols for functional software verification
- Creating, maintaining, and executing test plans
- Creating test reports
- Reporting issues clearly, including steps leading to the issue
- Collaborate with engineers and scientists to understand and document system and test requirements
- Diagnostic equipment or services in the life sciences industry knowledge/experience preferred
Alamar Biosciences focuses on the study of proteins, known as proteomics, to enhance disease detection and treatment. The company has created NULISA™, a technology that can detect and measure proteins in the human body with high sensitivity. This allows researchers and clinicians to profile clinically relevant protein biomarkers, which are essential for developing new diagnostic tests and treatments. Alamar's ARGO™ system complements NULISA™ by providing a fully automated platform for high-throughput precision proteomics, enabling users to analyze multiple protein targets in a single experiment. Unlike competitors, Alamar's technology simplifies the process, reducing the need for extensive technical expertise, making it accessible to a broader range of clients. The goal of Alamar Biosciences is to improve our understanding of proteins in health and disease, ultimately leading to better early detection and treatment options for various diseases.
Company Size
51-200
Company Stage
Grant
Total Funding
$225.7M
Headquarters
Hayward, California
Founded
2018
Simplify's Take
What believers are saying
- Certified Service Provider Program expands NULISA™ access to academia and biopharma researchers.
- $10M investment enhances ARGO™ DX System for Alzheimer's diagnostics, boosting market share.
- Collaboration with Michael J. Fox Foundation advances Parkinson's research and biomarker discovery.
What critics are saying
- Intellectual property disputes may arise with NULISAseq Inflammation Panel AQ launch.
- New competitors like Quantum-Si challenge Alamar's market share and pricing strategies.
- Reliance on partnerships exposes Alamar to risks if collaborations don't meet expectations.
What makes Alamar Biosciences unique
- Alamar's NULISA™ technology offers unprecedented sensitivity in protein detection and measurement.
- The ARGO™ system provides a fully automated, high-throughput precision proteomics platform.
- NULISAseq™ Inflammation Panel AQ sets a new standard in immune response profiling.
Help us improve and share your feedback! Did you find this helpful?
Benefits
401(k) Company Match
401(k) Retirement Plan
Performance Bonus
Company Equity
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↑ 0%2 year growth
↑ 7%FREMONT, Calif., Feb. 20, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of its Certified Service Provider (CSP) Program, designed to expand access to its cutting-edge NULISA™ assays in academia and biopharmaceutical research
Una herramienta revolucionaria que permite la cuantificación integral de la respuesta inmune en cohortes clínicas. FREMONT, Calif., 22 de enero de 2025 /PRNewswire/ -- Alamar Biosciences, una empresa que impulsa la proteómica de precisión para permitir la detección temprana de enfermedades, se enorgullece de anunciar el lanzamiento de NULISAseq™ Inflammation Panel AQ, que establece un nuevo estándar en la elaboración de perfiles de la respuesta inmunitaria en estudios clínicos o longitudinales. Diseñado para ofrecer una cobertura y precisión incomparables, el NULISAseq Inflammation Panel AQ permite a los investigadores descubrir nuevas características de la progresión de la enfermedad o la respuesta terapéutica con mediciones cuantitativas absolutas de más de 150 biomarcadores proteicos clave a partir de una sola muestra. Con una sensibilidad excepcional, el NULISAseq Inflammation Panel AQ permite la detección de niveles de citocinas tanto en estados normales como patológicos, lo que proporciona una plataforma sólida para el seguimiento de los cambios inmunitarios desde el inicio o después de intervenciones terapéuticas en cohortes clínicas. Esta solución transformadora redefine la precisión en el descubrimiento de biomarcadores y la investigación clínica
Revolutionary tool enables comprehensive quantitation of immune response in clinical cohorts.FREMONT, Calif., Jan. 22, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of the NULISAseq™ Inflammation Panel AQ, setting a new standard in profiling the immune response in clinical or longitudinal studies. Designed to deliver unparalleled coverage and precision, the NULISAseq Inflammation Panel AQ empowers researchers to discover novel signatures of disease progression or therapeutic response with absolute quantitative measurements of over 150 key protein biomarkers from a single sample.With exceptional sensitivity, the NULISAseq Inflammation Panel AQ enables the detection of cytokine levels in both normal and disease states, providing a robust platform for tracking immune changes from baseline or following therapeutic interventions in clinical cohorts. This transformative solution redefines precision in biomarker discovery and clinical research.Key features and benefits of the NULISAseq Inflammation Panel AQ:Unmatched Sensitivity: >99% quantifiability in normal samples allows researchers to detect subtle changes from baseline or after treatment, enabling more accurate monitoring of immune responses.Broad Dynamic Range: Over 9 logs dynamic range allows for simultaneous quantification of both high- and low-abundance proteins from the same sample, ensuring comprehensive data acquisition.High Reproducibility: Achieving a mean coefficient of variation (CV) of <10% ensures consistent and reliable results, even across large clinical studies."The NULISAseq Inflammation Panel AQ is the largest panel for absolute quantification available and represents a major leap forward in precision proteomics," said Yuling Luo, Chairman and CEO of Alamar Biosciences. "Its unprecedented sensitivity and dynamic range provide researchers with the tools to push the boundaries of immune system research, ultimately advancing our understanding of health and disease."The NULISAseq Inflammation Panel AQ is built on Alamar Biosciences' proprietary NULISA™ technology, which combines a patented sequential immunocomplex capture and release mechanism with next generation sequencing to deliver multiplexed, high sensitivity protein analysis. Using just 10μL of sample (25μL input), the panel addresses critical challenges in sample-limited studies, making it ideal for applications in oncology, autoimmune and infectious diseases.For more information about the NULISAseq Inflammation Panel AQ, visit alamarbio.com/inflamAQ.About Alamar Biosciences, Inc.Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease
The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) has invested $10M in Alamar Biosciences to advance precision medicine in Alzheimer's disease. This is the largest DxA investment to date, supporting the development of Alamar's ARGO™ DX System for in vitro diagnostic tests. The platform aims to create a scalable blood panel for detecting multiple biomarkers, enhancing early detection and personalized treatment in Alzheimer's.
Alzheimer's Drug Discovery Foundation invests $10M in Alamar Biosciences.